Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
Michael Kors CEO: We're Actively Looking At M&A Options
Najarian Brothers See Unusual Options Activity In Perrigo And Restoration Hardware
One 20% Dividend Increase Expected Among 8 Announcements In 2nd Half Of February (Seeking Alpha)
Related IPXL
FTC Keeps Pressure On Wall Street, Refiles Suit Against Allergan, Others
Benzinga's Top Upgrades, Downgrades For December 28, 2016

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News


Related Articles (IPXL + PRGO)

View Comments and Join the Discussion!